HSIC — Henry Schein, Inc.

Sentiment turned constructive after the August 4, 2026 Q2 2026 print: global sales of $3.458B (+6.7% YoY, +4.6% internal local currency) and non-GAAP diluted EPS of $1.27 (+15.5% YoY) beat consensus, and management raised FY2026 guidance to 4.5-5.5% sales growth and $5.29-$5.39 non-GAAP EPS (from $5.23-$5.37). Sell-side followed with target hikes — BTIG $100 to $110, Citigroup $100 to $112, Barclays $86 to $100, Baird $109 — and the ratings mix of 17 Buy / 14 Hold / 3 Sell is a genuine moderate-buy. Against that, the consensus target of $92.33 sits only ~4.5% above the 2026-09-13 price of $88.36 and the low target of $64 shows real dispersion, so this is bullish sentiment that is already substantially reflected in the tape rather than a fresh catalyst ahead.

Revenue has clearly inflected and is now accelerating rather than merely stable: $3,162M (Q3'23) -> $3,017M (Q4'23) -> $3,172M (Q1'24) -> $3,136M (Q2'24) -> $3,174M (Q3'24) -> $3,191M (Q4'24) -> $3,168M (Q1'25) -> $3,240M (Q2'25) -> $3,339M (Q3'25) -> $3,437M (Q4'25) -> $3,368M (Q1'26) -> $3,458M (Q2'26). YoY growth went roughly -0.1% (Q1'25), +3.3% (Q2'25), +5.2% (Q3'25), +7.7% (Q4'25), +6.3% (Q1'26), +6.7% (Q2'26) — this is a structural inflection out of the ~0-1% growth of 2024, not a one-quarter blip. The cleanest improving line is gross margin, up from 28.7% in Q4'23 to 31.8% in both Q1'26 and Q2'26 (~+240bp over two years). Operating margin, however, is basically flat: 5.78% in Q2'26 vs 5.40% in Q2'25, and 5.69% on a trailing-twelve-month basis vs 6.06% a year earlier, because SG&A rose to ~26.1% of sales in Q2'26 from ~24.0% in Q2'25 and absorbed essentially the entire gross-margin gain. Reported profit is remarkably static — GAAP net income of $94M in Q2'26 vs $86M in Q2'25 and $104M in Q2'24 — so nearly all of the earnings growth lives in the non-GAAP bridge (Q2'26 GAAP EPS of $0.82 vs non-GAAP $1.27, with a $0.14 GAAP trough in Q4'23). Free cash flow is trending better: $539M TTM through Q2'26 vs $358M in the prior TTM window, though Q1'26 FCF of -$136M versus -$6M in Q1'25 is a working-capital swing worth watching.

Fair, with a large GAAP/non-GAAP caveat that cuts both ways. As of 2026-09-13 at $88.36, HSIC trades at 25.5x TTM GAAP EPS of $3.55 and 3.18x book, against a 5-year average TTM P/E of 21.5x — so on reported earnings it screens expensive. On the FY2026 non-GAAP guidance midpoint of $5.34 it is ~16.5x, and on my FY2027 estimate of ~$5.85 it is ~15.1x, which is roughly in line with healthcare-distribution peers despite a materially worse ROIC (6.6% vs peers in the low-to-mid teens). Price/sales of 0.74 is actually below the 5-year average of 0.79, and TTM FCF of $539M is a ~5.4% free-cash-flow yield. The 2.51 PEG is not meaningful because the TTM GAAP base is depressed by amortization and restructuring. Net: not cheap, not stretched — the stock is priced for the cost-savings program to land rather than for a further re-rating.

The roughly 43% move off the $61.95 52-week low to $88.36 happened while GAAP EPS went essentially nowhere — this is multiple expansion and anticipation of the $125M cost run-rate, not delivered reported earnings. That creates a specific asymmetry: if FY2027 adjusted EPS lands at $5.85-$6.20 as the cost program and cloud mix suggest, the stock at $88.36 is ~14-15x, which is reasonable for a low-beta, 0.81-beta healthcare distributor with recurring software revenue; if the cost program slips or dental equipment demand rolls over, the buyer is left with a 25x trailing-GAAP, 3.0% net margin, 6.6% ROIC distributor. Analyst targets cluster at $92.33 consensus / $96.71 recent average / $110-112 high, implying only ~5-15% upside, with a $64 low target showing the bear case is real. In other words, execution is largely priced in; you are being paid for the income statement turning into the guidance, not for a bargain.

As of 2026-09-13, RSI(14) stood at 48.81 — dead neutral, neither overbought nor oversold after a -2.62% month and -1.61% week. Using the 2026-09-13 price of $88.36 and the reported spreads, the derived SMA20 is ~$89.30 (-1.05%), SMA50 ~$87.74 (+0.71%), and SMA200 ~$79.42 (+11.26%): a firm intermediate and long-term uptrend that has stalled into a short-term range roughly 3.8% below the $92.18 52-week high. This is consolidation, not breakdown, and an RSI near 50 means there is room in either direction. Constructive entries would come on a hold of the 50-day (~$87.7 area as of this date) or a decisive break above $92.18; a close below the 200-day would say the re-rating has run its course.

• Office-based dental and medical practice economics: equipment purchases are discretionary capex for small practices, so patient visit volumes, practice cash flow and DSO (dental service organization) consolidation drive the higher-margin equipment line; the research brief notes dental traffic and elective spending have held up, which is the key support for the 4.6% internal growth.
• Interest rates and leverage: HSIC carries roughly $2.3B of long-term debt plus other borrowings against just $157M of cash (total debt/equity 1.21, current ratio 1.32, quick ratio 0.73), so a high-for-longer rate environment raises interest expense and limits how aggressively the company can keep repurchasing stock ($200M / ~2.6M shares in Q2 2026).
• Tariffs and import cost pass-through: as a distributor of globally sourced equipment and consumables, gross margin is exposed to tariff changes and vendor price increases that cannot always be passed to independent practices quickly — the flip side is that supply-chain normalization is currently a documented tailwind to gross margin.
• Cloud/software mix shift: migration from legacy on-premise practice management to cloud platforms (Dentrix Ascend at roughly $800 monthly revenue per user) is a durable, stickier revenue tailwind, but the transition temporarily depresses reported margins as high-upfront legacy license revenue declines.
• Reimbursement and regulatory environment: Medicaid/insurance reimbursement policy and healthcare regulation affect the small-practice customer base's willingness to spend, and any tightening pressures both consumables volumes and equipment financing.

• Q3 2026 earnings in late October / early November 2026 — the first real test of whether the raised FY2026 guide (4.5-5.5% sales growth, $5.29-$5.39 non-GAAP EPS) is on track; failure to confirm would undercut the entire re-rating.
• Delivery of the value-creation program: management targets a $125M run-rate by the end of 2026 and over $200M of cumulative operating income improvement over the next few years — this is the single biggest bridge from ~$5.34 FY2026 EPS to a $6+ FY2027 number.
• Cloud dental software scaling (record Dentrix Ascend sign-ups in June 2026) and the associated higher revenue per user, which improves revenue quality and mix over time.
• Continued share repurchases — $200M in Q2 2026 alone (~2.6M shares against a ~114M share count), which mechanically lifts EPS even with flat net income.

• Earnings quality: Q2 2026 GAAP EPS of $0.82 versus $1.27 non-GAAP, TTM GAAP EPS of $3.55, and a 3.0% net margin mean the 'beat and raise' narrative rests on adjusted numbers that exclude a large, recurring-looking gap.
• Returns below cost of capital: ROIC of 6.6% versus ROE of 12.3% shows leverage flattering equity returns, not superior business economics; if the cost program does not lift ROIC, the multiple has no structural support.
• Balance-sheet thinness: only $157M cash, quick ratio 0.73, current ratio 1.32 and total debt/equity of 1.21 leave limited cushion, and cash flow is seasonally volatile (Q1 2026 operating cash flow of -$97M and FCF of -$136M versus +$37M / -$6M in Q1 2025).
• Discretionary equipment demand: if practice capex or patient volumes weaken, the 6-7% revenue growth that underpins the whole re-rating reverses quickly, and gross-margin gains from supply-chain normalization are not permanent.
• Competitive pressure: e-commerce and direct-from-manufacturer selling into independent practices, plus DSO consolidation creating larger buyers with more pricing power, pressure the distribution margin over the long run.

This is a decent, not compelling, holding at $88.36. The direction is genuinely good — revenue growth has inflected from ~0-1% to 5-7%, gross margin is up ~240bp over two years, TTM free cash flow rose from $358M to $539M, guidance was raised on August 4, 2026, and four brokers moved targets into the $100-112 range. But the underlying economics remain mediocre: 6.6% ROIC, 3.0% net margin, a $3.55 GAAP TTM EPS against a $5.29-$5.39 adjusted guide, and a flat operating margin because SG&A has eaten the entire gross-margin gain. At ~16.5x FY2026 guidance and only ~5% below the consensus target, the stock already reflects the cost-savings story. Buy it on a pullback toward the high $70s/low $80s where the forward multiple gets genuinely cheap; at the 2026-09-13 price the risk/reward is balanced.

I apply 16.5x to my FY2027 non-GAAP EPS estimate of $5.85 — FY2026 guidance midpoint of $5.34 grown ~10%, reflecting the $125M cost-program run-rate exiting 2026 plus low-single-digit organic growth — giving ~$96.5; the 16.5x sits at the low end of HSIC's historical forward non-GAAP range and in line with distributor peers, a discount justified by 6.6% ROIC and 1.21x debt/equity. I cross-check that with a free-cash-flow approach — normalized FCF of roughly $600M, or ~$5.26 per share on ~114M shares, capitalized at a 5.5% yield, giving ~$95.6. Blending the two and shading slightly for the thin $157M cash balance, I set fair value at $95, about 7.5% above the 2026-09-13 price of $88.36 and in the upper half of the current analyst target range.